IVA Earnings Date: Mar 31, 2027 (Estimated) — Inventiva S.A.
NASDAQ · Healthcare · Biotechnology
Updated
When is IVA's next earnings date?
Inventiva S.A. (IVA) is expected to report FY 2026 earnings on Wednesday, March 31, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.52 on revenue of $7.0M.
How did IVA do in its last earnings report?
In its most recent report on Sep 28, 2026 (H1 2026), Inventiva S.A. posted EPS of -$0.29 versus the -$0.20 estimate, a miss of 45.0%. Revenue was $23,251 against a $2.9M estimate. The stock's 1-day post-earnings move was +4.7%.
How much does IVA stock move after earnings?
IVA beat EPS estimates in 0 of its last 3 reported quarters. Over the last 8 reports the stock moved an average of 5.8% (up or down) in the day after earnings.
About Inventiva S.A.
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-28 | H1 2026 | -0.20 | -0.29 | -45.00% | $23,251 | ❌ Miss | +4.75% | +5.64% | +8.61% |
| 2026-03-30 | FY 2025 | -1.66 | -2.14 | -28.92% | $5.1M | ❌ Miss | +1.28% | -2.55% | -9.85% |
| 2025-09-29 | H1 2025 | -0.41 | -1.84 | -348.05% | $5.0M | ❌ Miss | -2.98% | +7.93% | +14.05% |
| 2025-03-26 | FY 2024 | — | -3.33 | — | $10.0M | — | +5.86% | +7.83% | +35.30% |
| 2024-09-25 | H1 2024 | — | -1.01 | — | $44,141 | — | -17.32% | -13.17% | +14.55% |
| 2024-03-27 | FY 2023 | — | -2.62 | — | $18.8M | — | -5.24% | -4.19% | -14.92% |
| 2023-09-28 | H1 2023 | — | -1.42 | — | $2.1M | — | -1.41% | -3.76% | -13.15% |
| 2023-03-29 | FY 2022 | — | -1.34 | — | $12.4M | — | -7.71% | -7.85% | -27.66% |
Showing last 8 quarters.